NPRL3 and cancer: For example, GOLGA7, ITPK1, and NPRL3 were correlated with increased drug resistance of cancer cells to Dasatinib, Zoledronate, PF-06463922, Brigatinib, LDK-378, Vinorelbine, Carfilzomib, and Bortezomib, respectively.